What is a supplement and nutraceutical brand worth?

A supplement and nutraceutical brand is worth what a buyer will pay for a catalogue of products that can keep being lawfully sold the day after closing, which makes the state of its Health Canada licensing as central to the price as the formulation, the margins or the sales channel. Two brands can carry near-identical revenue, similar margins and comparable social followings and still receive very different offers, because the one with a complete, current licence file behind every product it actually sells is a fundamentally safer asset than the one carrying even a single unlicensed or pending SKU.

A valid Natural Product Number on every SKU — not just the flagship product

Buyers and their advisors check licensing status product by product against what is actually being sold on the storefront right now, not against what the brand’s marketing materials claim or what was true when the flagship product first launched. A brand that has quietly added new flavours, formats or line extensions without securing a Natural Product Number for each one is carrying real, undisclosed regulatory exposure, and that exposure attaches to whoever owns the company at the time it surfaces — which is exactly why it gets priced into the deal rather than treated as a minor administrative gap.

Single-source manufacturing is a discount, not a footnote

A formulation and supply chain that depends on one contract manufacturer with no qualified backup is a fragile asset, because if that facility loses its site licence, hits a capacity constraint or simply raises its prices, the brand has no fallback and the buyer inherits that fragility along with everything else. A brand that has deliberately built a relationship with a second qualified manufacturer, even if it is rarely used, is a meaningfully stronger asset than one that has never tested whether its formulation can actually be produced anywhere else, and buyers price that difference even when both brands report similar current margins.

Expiry-dated inventory does not count at full value

Inventory sitting close to its labelled expiry or best-before date has to be written down rather than counted at cost when a buyer is assessing what they are actually paying for, because product that cannot be sold through before it expires is closer to a disposal cost than an asset. A brand carrying a large batch of slow-moving inventory nearing its date is effectively asking the buyer to absorb that shrinkage, and a careful buyer will want to see the actual expiry schedule broken out by SKU rather than accepting a single inventory total at face value.

How the earnings actually get recast here

Recasting earnings for a supplement brand starts with the usual adjustments — founder compensation, one-off marketing spend, above-market contractor costs — but then has to be weighed against the size of any expiry-driven inventory write-down and the cost of closing whatever licensing gaps exist before the business can be sold with a clean file. A buyer’s advisor will typically build a recast that assumes the cost of bringing every SKU into full compliance and replacing any expiring inventory, and price closer to that conservative version than to the seller’s optimistic starting number.

Why two similar-looking brands price differently

The brand with full-portfolio licence coverage, a documented backup manufacturer and label claims that stay within what its Natural Product Number actually authorizes will consistently price higher than a brand with comparable revenue but gaps in any one of those three areas, because each gap represents a specific, quantifiable cost or risk a buyer has to absorb after closing rather than a vague concern. This is the reason sub-sector-specific diligence matters so much more here than a generic revenue multiple — the regulatory file is not a formality sitting alongside the real asset, it is a large part of the asset itself.

Why the buyer bidding changes the number

A strategic consumer-health acquirer adding the brand to an existing regulated portfolio can often absorb a licensing gap or a single-manufacturer dependency more comfortably than an independent buyer, because it already has its own regulatory-affairs team and manufacturer relationships to fall back on — which means it may price a flawed file less harshly than the mechanics above would suggest. A private-equity buyer experienced in regulated consumer products tends to do the opposite, pricing almost entirely off the completeness of the licensing file and the supply-chain documentation, since that is precisely the risk its underwriting is built to catch. An existing supplement brand acquiring an adjacent product line usually prices the licence portfolio itself as a distinct, valuable asset — sometimes the main reason for the deal — because absorbing an already-licensed catalogue is faster than building new Natural Product Numbers from scratch.